Morphic Holding, Inc. MORF
We take great care to ensure that the data presented and summarized in this overview for Morphic Holding, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MORF
View all-
Wellington Management Group LLP Boston, MA5.81MShares$331 Million0.04% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.98MShares$284 Million6.0% of portfolio
-
Black Rock Inc. New York, NY3.53MShares$201 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N42.53MShares$144 Million5.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.22MShares$126 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.21MShares$126 Million0.01% of portfolio
-
Woodline Partners LP San Francisco, CA1.78MShares$102 Million0.61% of portfolio
-
State Street Corp Boston, MA1.64MShares$93.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.46MShares$83.3 Million0.14% of portfolio
-
Pictet Asset Management Sa Geneva 73, V81.06MShares$60.5 Million0.07% of portfolio
Latest Institutional Activity in MORF
Top Purchases
Top Sells
About MORF
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Insider Transactions at MORF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 16
2024
|
Martin Edwards |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,376
-100.0%
|
-
|
|
Aug 16
2024
|
Timothy A Springer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,811,766
-100.0%
|
-
|
|
Aug 16
2024
|
Timothy A Springer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
4,608,052
-100.0%
|
-
|
|
Aug 16
2024
|
Amir Nashat |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
1,990,651
-100.0%
|
-
|
|
Aug 16
2024
|
Amir Nashat |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
145
-100.0%
|
-
|
|
Aug 16
2024
|
Joseph P Slattery |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,066
-100.0%
|
-
|
|
Aug 16
2024
|
Gustav Christensen |
SELL
Sale (or disposition) back to the issuer
|
Direct |
100,517
-100.0%
|
-
|
|
Aug 16
2024
|
Praveen P. Tipirneni President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
614,474
-100.0%
|
-
|
|
Aug 16
2024
|
Praveen P. Tipirneni President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
42,460
-100.0%
|
-
|
|
Aug 16
2024
|
Bruce Rogers PRESIDENT |
SELL
Sale (or disposition) back to the issuer
|
Direct |
149,883
-100.0%
|
-
|
|
Aug 16
2024
|
William De Vaul General Counsel and Secretary |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,587
-100.0%
|
-
|
|
Aug 16
2024
|
Robert E Farrell Jr SVP Finance and CAO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,000
-100.0%
|
-
|
|
Aug 16
2024
|
Marc Schegerin CFO and COO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
37,907
-100.0%
|
-
|
|
Aug 06
2024
|
William De Vaul General Counsel and Secretary |
SELL
Bona fide gift
|
Direct |
4,000
-16.96%
|
-
|
|
Aug 02
2024
|
Robert E Farrell Jr SVP Finance and CAO |
SELL
Bona fide gift
|
Direct |
2,000
-14.51%
|
-
|
|
Jul 08
2024
|
Bruce Rogers PRESIDENT |
SELL
Open market or private sale
|
Direct |
20,000
-11.77%
|
$1,100,000
$55.79 P/Share
|
|
Jul 08
2024
|
Bruce Rogers PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+10.53%
|
$80,000
$4.32 P/Share
|
|
Jul 08
2024
|
William De Vaul General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
10,000
-30.28%
|
$550,000
$55.79 P/Share
|
|
Jul 08
2024
|
William De Vaul General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+23.24%
|
$40,000
$4.32 P/Share
|
|
Jul 08
2024
|
Robert E Farrell Jr SVP Finance and CAO |
SELL
Open market or private sale
|
Direct |
30,272
-68.72%
|
$1,664,960
$55.8 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 4.78K shares |
|---|---|
| Exercise of conversion of derivative security | 224K shares |
| Disposition due to a tender of shares in a change of control transaction | 10.1M shares |
|---|---|
| Sale (or disposition) back to the issuer | 331K shares |
| Open market or private sale | 162K shares |
| Bona fide gift | 6K shares |